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Background: Retinitis pigmentosa (RP) is an inherited human retinal disorder that causes progressive photoreceptor
cell loss, leading to severe vision impairment or blindness. However, no effective therapy has been established to date.
Although genetic mutations have been identified, the available clinical data are not always sufficient to elucidate the
roles of these mutations in disease pathogenesis, a situation that is partially due to differences in genetic backgrounds.
Results: We generated induced pluripotent stem cells (iPSCs) from an RP patient carrying a rhodopsin mutation
(E181K). Using helper-dependent adenoviral vector (HDAdV) gene transfer, the mutation was corrected in the
patient’s iPSCs and also introduced into control iPSCs. The cells were then subjected to retinal differentiation; the
resulting rod photoreceptor cells were labeled with an Nrl promoter-driven enhanced green fluorescent protein
(EGFP)-carrying adenovirus and purified using flow cytometry after 5 weeks of culture. Using this approach, we found a
reduced survival rate in the photoreceptor cells with the E181K mutation, which was correlated with the increased
expression of endoplasmic reticulum (ER) stress and apoptotic markers. The screening of therapeutic reagents showed
that rapamycin, PP242, AICAR, NQDI-1, and salubrinal promoted the survival of the patient’s iPSC-derived photoreceptor
cells, with a concomitant reduction in markers of ER stress and apoptosis. Additionally, autophagy markers were found
to be correlated with ER stress, suggesting that autophagy was reduced by suppressing ER stress-induced apoptotic
changes.
Conclusion: The use of RP patient-derived iPSCs combined with genome editing provided a versatile cellular
system with which to define the roles of genetic mutations in isogenic iPSCs with or without mutation and also
provided a system that can be used to explore candidate therapeutic approaches.
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currently no cure for this disease.
Approximately 3,000 mutations have been reported
in 50 genes in RP patients [1], and more than 100 point
mutations have been identified in the rhodopsin gene
[2]. Rhodopsin, an evolutionarily conserved seven-
transmembrane protein specifically produced in photo-
receptor cells, is first localized to the endoplasmic reticulum
(ER) and is then transported to the outer segment discs
where it responds to photon activation via conformational
changes. Pathological responses to genetic mutations in
rhodopsin typically occur in an autosomal dominant man-
ner due to the production of an abnormal protein. Somel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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retained in ER; in some cases, the mutant proteins are
bound by the ER-resident chaperone, BiP [3]. The accu-
mulated mutant proteins may induce unfolded-protein
response (UPR) to alleviate the ER stress. In general, the
abnormal proteins could be degraded through ubiquitin
proteasome pathway and/or autophagy [4]. However, if
the mutant protein was overloaded, the prolonged UPR
will induce ER stress-associated programmed cell death,
apoptosis [5]. Although many rhodopsin gene abnor-
malities are believed to be related to ER stress [3], prac-
tical therapies targeting mutant rhodopsin proteins or
downstream signaling pathways have yet to be estab-
lished. This may be due, in part, to the insufficient un-
derstanding of the disease pathogenesis: mutations
associated with RP are genetically heterogeneous, and,
in most cases, there is no formal proof of a causal re-
lationship between the genetic mutation and the RP
phenotype. Furthermore, only a limited number of gen-
etic abnormalities have been reproduced and studied
in Drosophila [6] and mouse systems [7,8], and drug
screening is not easily performed due to the lack of appro-
priate screening systems. Although the abnormal gene of
interest can be expressed in cell lines, overexpression
commonly results in artificial cellular responses.
In an effort to develop an authentic cell-based model
of human RP, induced pluripotent stem cell (iPSC) tech-
nology [9,10] has been recently applied to this disorder
[11,12]. However, a causal relationship between genetic
mutations and the RP phenotype remains to be eluci-
dated. In the present study, we generated iPSCs from
the somatic cells of an RP patient carrying a heterozy-
gous mutation in the rhodopsin gene [13]. These cells
were then differentiated into rod photoreceptor cells to
investigate the cellular pathogenesis of RP and to screen
chemical therapeutics. A comparison of the RP and con-
trol iPSC-derived photoreceptor cells showed that the
RP patient’s iPSC-derived rod photoreceptor cells had a
reduced survival rate in culture and an increased ER
stress response. Furthermore, to formally demonstrate
that the phenotype was due to the expression of mutant
rhodopsin, we utilized the helper-dependent adenoviral
vector (HDAdV) to replace the mutated rhodopsin gene
in the RP patient’s iPSCs with the wild-type rhodopsin
gene, thus repairing the gene, and found that the pheno-
type of the iPSC-derived photoreceptor cells reverted to
normal. This method allowed a phenotypic comparison
between the iPSC-derived photoreceptor cells of the same
genetic background and developmental course during iPSC
generation. Moreover, replacing the wild-type gene in the
control iPSCs with a mutated gene using HDAdV recon-
structed the pathological condition. We next used the RP
patient’s iPSC-derived photoreceptor cells to screen for
chemical reagents that rescued the ER stress phenotype.The involvement of autophagy, which can be induced in
response to ER stress [14], was also explored.
Results
Generation of iPSCs from an RP patient
The iPSC line RP#5 (#5) was generated using skin cells
[15] isolated from an RP patient carrying a rhodopsin mu-
tation (a G to A substitution at nucleotide 541) (Figure 1A)
[13]. The point mutation resulted in a change in amino
acid 181 from a glutamic acid (E) to lysine (K) (E181K)
and was shown to be present on one allele in the #5 iPSCs
but not in the 201B7 (B7) iPSCs (Figure 1B). The expres-
sion of pluripotent markers (Figure 1C-E) and the forma-
tion of teratomas containing all three germ layer cells
(Figure 1F) were also confirmed.
Preparation of gene-targeted iPSC lines
To determine whether the expression of rhodopsin
E181K was solely responsible for the accelerated photo-
receptor cell loss, we prepared rhodopsin gene-targeted
iPSCs using HDAdVs. A wild-type rhodopsin gene in a
BAC clone, with a Neo cassette introduced in the third
intron, was inserted into an HDAdV vector to generate
the correction vector (Figure 2A). Using this correction
vector, the wild-type rhodopsin gene was replaced with
the genome sequence of the #5 iPSCs through homolo-
gous recombination, followed by the removal of the Neo
cassette by Cre recombinase to generate #5Rw iPSCs
(Figure 2A). Similarly, the mutated rhodopsin sequence
obtained from the genome of the #5 iPSCs was inserted
into an HDAdV vector to construct a mutagenesis vec-
tor (Figure 2B) that was transferred into the genome of
B7 iPSCs, followed by the removal of the Neo cassette,
to generate B7Rm iPSCs (Figure 2B).
The introduction and removal of the Neo cassette at
the rhodopsin locus were confirmed by PCR analyses
(Figure 2C). We further confirmed the absence of the
rhodopsin point mutation in the #5Rw cells and the pres-
ence of the heterozygous point mutation in the B7Rm cells
(Figure 2D). These data indicated that the targeted rhod-
opsin gene correction and mutagenesis were successful.
Impact of the rhodopsin gene mutation in differentiated
rod photoreceptor cells derived from iPSC lines
Next, we induced retinal cell differentiation using the
serum-free embryoid body (SFEB) method, along with sub-
sequent stepwise changes in the culture medium for sev-
eral weeks, as previously reported and modified by Lamba
et al. [16]. iPSCs were cultured in the presence of Noggin,
Dkk-1, and IGF-1 for 3 weeks, followed by 2 weeks of
culture in their absence [16]. Using this method, up to 10%
of the differentiated cells were reported to express early
markers of photoreceptor differentiation at the end of
3 weeks, and these cells can be transplanted into subretinal
Figure 1 RP patient’s iPSCs. (A) A colony of RP#5 iPSCs derived from an RP patient’s skin cells. (B) DNA analysis of the rhodopsin gene in the
RP#5 iPSCs and control 201B7 iPSCs. (C-E) Immunostaining for pluripotent markers; the nuclei were counterstained with DAPI (blue). (C) Nanog
and Oct3/4. (D) Tra-1-60. (E) SSEA4. (F) Teratoma formation assay showing that the RP#5 iPSCs gave rise to all three germ layers, confirming their
pluripotency. Scale bar, 1 mm (A), 250 μm (C-F).
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synapses [16-18]. In the present study, a recombinant
adenovirus expressing EGFP under the control of the
neural retina leucine zipper promoter, a rod photoreceptor-
specific marker that acts as a transcription factor for the
rhodopsin gene, (Ad-pNrl-EGFP) [19-21], was introduced
2 days before flow cytometry analyses (Figure 3A, B). The
specific detection of EGFP by flow cytometry was con-
firmed using the cells with (Figure 3C right) and without
Ad-pNrl-EGFP infection (Figure 3C left). This experiment
also confirmed that 32.8% of the cells were Ad-pNrl-
EGFP positive after 5 weeks of culture. Among the Ad-
pNrl-EGFP-positive cells derived from the #5 iPSCs, we
confirmed that recoverin, a photoreceptor marker, was up-
regulated after 5 weeks in differentiation culture compared
to the non-differentiated #5 iPSCs (Figure 3D).Using this method, rod photoreceptor cells derived from
each iPSC line (#5, #5Rw, B7, and B7Rm) were quantified
weekly from 2 to 5 weeks after differentiation was initiated
(Figure 3E). During the first 4 weeks of culture, the pro-
portion of Ad-pNrl-EGFP-positive rod photoreceptor cells
gradually increased with time, and there was no difference
among the cell lines. However, after 5 weeks in differenti-
ation culture, the proportion of rod photoreceptor cells
was significantly higher in the cultures derived from the
#5Rw and B7 iPSC lines, which did not contain the
mutated rhodopsin coding sequences, compared to the
#5 and B7Rm lines, which did contain the mutation
(Figure 3E, F). Furthermore, we investigated the ratio of
apoptotic cells of pNrl-EGFP-positive rod photoreceptor
cells derived from #5 and #5Rw iPSCs, by immunostaining
using an anti-Annexin V antibody (Figure 3G) and by PI
Figure 2 The rhodopsin gene-targeting methods. (A, B) Schematic illustrations of the rhodopsin gene correction implemented in the RP#5
iPSCs and the mutagenesis in the 201B7 iPSCs using HDAdVs. (C) A PCR analysis confirmed that recombination occurred at the rhodopsin locus.
Products of 4.2 kb and 15.8 kb were obtained using primers a-b and c-d (arrowheads in A, B), respectively. (D) Sequence analysis of the
recombinant rhodopsin genes in each iPSC line. HDAdV, helper-dependent adenoviral vector; HSV-tk, herpes simplex virus thymidine kinase gene
cassette; Neo, neomycin-resistance gene cassette; white triangles, loxP sites; red boxes, exon 3 of rhodopsin containing the E181K mutation.
#5, RP#5 iPSCs; #5Rw, rhodopsin gene-corrected RP#5 iPSCs; B7, 201B7 iPSCs; B7Rm, rhodopsin gene-mutated 201B7 iPSCs.
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from #5 iPSCs included more apoptotic cells than those
derived from #5Rw iPSCs, suggesting that the lower num-
ber of the rod differentiated photoreceptor cells derived
from #5 than from #5Rw iPSCs was caused, at least in
part, by the enhanced apoptosis of rod photoreceptor cells
derived from #5 iPSCs. These data collectively indicated
that the rhodopsin E181K mutation was solely responsible
for the rod photoreceptor cell loss associated with this
patient.
Because ER stress has been implicated in the patho-
genesis of RP that involves rhodopsin mutations [3], we
analyzed the expression of the ER stress markers BiP(Figure 3I) and CHOP (Figure 3J) using real-time PCR
analyses. For this purpose, we purified the Ad-pNrl-EGFP
cells using flow cytometry and extracted mRNA from
the Ad-pNrl-EGFP-positive rod photoreceptor cells. The
mRNA levels of both BiP and CHOP were elevated in the
#5 and B7Rm iPSC-derived rod photoreceptor cells after
5 weeks in differentiation culture. Furthermore, we also
examined the apoptosis-related molecules BID (Figure 3K)
and NOXA (Figure 3L). After 5 weeks of culture, these
molecules were also upregulated in the purified Ad-pNrl-
EGFP-positive rod photoreceptor cells derived from the
#5 and B7Rm iPSCs, suggesting that the mutant rhodop-
sin protein induced ER stress and apoptosis.
Figure 3 Impact of the E181K rhodopsin gene mutation on rod photoreceptor cells derived from iPSC lines. (A) Protocol of rod photoreceptor
cell differentiation. (B) Expression of the rod photoreceptor cell-specific gene Nrl was visualized by infection with the Ad-pNrl-EGFP virus. (C) Flow
cytometry analysis of the differentiated cells without (left) and with (right) Ad-pNrl-EGFP infection at 5 weeks. (D) The recoverin mRNA levels of the flow
cytometry-purified pNrl-EGFP-positive rod photoreceptor cells derived from the #5 iPSCs compared to the undifferentiated #5 iPSCs at the same time
point. (E) Quantification of the pNrl-EGFP-positive rod photoreceptor cells in each iPSC line after 2, 3, 4, and 5 weeks of differentiation. Red, B7; blue,
#5Rw; pink, B7Rm; green, #5. N = 9. (F) Proportion of pNrl-EGFP-positive rod photoreceptor cells derived from iPSC lines after 5 weeks. N = 9. (G, H) The
ratio of dead cells in pNrl-EGFP-positive photoreceptor cells detected by Annexin V (G) and PI (H). N = 4. (I-L) Relative mRNA levels of BiP (I), CHOP (J),
BID (K), and NOXA (L) normalized to b-Actin in the pNrl-EGFP-positive cells collected after 5 weeks, as determined by a real-time PCR analysis. N = 3.
Ad-pNrl-EGFP, adenovirus promoter Nrl-EGFP. *p < 0.05. Scale bar, 40 μm. Mean ± SD (with each p-values of marked by *) for iPSCs and pNrl-EGFP
cells in (D) 1 ± 0.38, 13.6 ± 0.14 (p = 0.049); for #5, #5Rw, B7, B7#Rm in (F) 34.6 ± 11.7, 55.7 ± 10.0 (p = 0.035), 64.3 ± 11.3, 38.9 ± 5.8 (p = 0.013); for #5 and
#5Rw in (G) 1 ± 0.18, 0.16 ± 0.02, (p = 0.019) (H) 1 ± 0.24, 0.24 ± 0.07 (p = 0.021); for #5, #5Rw, B7, B7#Rm in (I) 1 ± 0.005, 0.83 ± 0.002 (p < 0.0001),
0.95 ± 0.006, 1.33 ± 0.004 (p < 0.0001); (J) 1 ± 0.002, 0.76 ± 0.007 (p < 0.0001), 0.79 ± 0.005, 1.03 ± 0.010 (p < 0.0001); (K) 1 ± 0.016, 0.88 ± 0.006 (p = 0.003),
0.94 ± 0.008, 1.14 ± 0.013 (p < 0.0001); (L) 1. ± 0.005, 0.75 ± 0.005 (p < 0.0001), 0.77 ± 0.005, 0.80 ± 0.004 (p = 0.001). All statistical analyses in this figure
were carried out by Student’s T test.
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from RP iPSCs
To explore treatments that may protect rod photoreceptor
cells from the accelerated cell loss induced by the rhodop-
sin mutation, we treated the cells with reagents that could
modify ER stress-related pathways and quantified the
Ad-pNrl-EGFP-positive rod photoreceptor cells using flow
cytometry after 5 weeks in differentiation culture. Thereagents were added to the medium after 3 weeks of cul-
ture and were re-added each time the medium was chan-
ged (every 2–3 days). After 5 weeks of culture, the number
of #5 iPSC-derived rod photoreceptor cells collected and
counted by flow cytometry was significantly increased fol-
lowing treatment with rapamycin and PP242 (both mTOR
inhibitors), AICAR (an activator of AMP kinase [AMPK]),
NQDI-1 (an inhibitor of apoptosis signal-regulating kinase
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lation initiation factor 2 subunit α [eIF2α] phosphatase
and protein synthesis) (Figure 4A). These data showed that
the E181K mutant rhodopsin-related cell loss could be
suppressed by mTOR inhibition, AMPK activation, ASK1
inhibition, or the suppression of protein synthesis.
Effect of treatments on ER stress and apoptosis markers
Next, we investigated the effects of reagents on ER stress
markers in the #5 iPSC-derived rod photoreceptor cells.
After the Ad-pNrl-EGFP-positive cells were purified and
treated with the above-mentioned reagents, mRNA was
harvested from the cells and analyzed using real-time
PCR. The mRNA levels of BiP and CHOP were found to
be reduced following rapamycin, PP242, AICAR, NQDI-
1, or salubrinal treatment (Figure 4B, C) in the Ad-pNrl-
EGFP-positive rod photoreceptor cells, suggesting that
these reagents suppressed the ER stress caused by the
mutant rhodopsin. Additionally, the expression levels of
apoptosis-related molecules, which were upregulated in
the rod photoreceptor cells expressing the mutant rhod-
opsin, were decreased following the addition of these
same drugs (Figure 4D, E).
Involvement of autophagy
As ER stress is known to activate autophagy to overcome
cellular dysfunction, we examined autophagy markers in
each line of iPSC-derived rod photoreceptor cells in the
presence and absence of treatment with different drugs.
We first examined LC3 immunostaining that indicates
a putative autophagosome in pNrl-EGFP-positive photo-
receptor cells (Figure 5A-L), and found that the presence
of LC3 was obvious in the cells with rhodopsin mutation
(Figure 5D-I), but hardly detected in the cells without the
mutation (Figure 5A-C, J-L). The autophagy markers LC3,
Atg5, and Atg7 were all suppressed in the #5Rw and
B7 iPSC-derived rod photoreceptor cells compared to theFigure 4 Drug screening in the RP #5 iPSC-derived rod photorecepto
cells derived from #5 iPSCs after treatment with each therapeutic reagent.
NOXA (E) in the pNrl-EGFP-positive cells cultured with rapamycin, PP242, A
reagent increased the rod photoreceptor cell survival at 5 weeks, whereas
Rapa., rapamycin; Salub., salubrinal. *p < 0.05, **p < 0.01, ***p < 0.001. Mean
Rapa., PP242, AICAR, NQDI-1, Salbr. in (A) 1 ± 0.182, 3.02 ± 0.920, 3.49 ± 0.97
0.654 ± 0.001, 0.990 ± 0.001, 0.932 ± 0.001, 0.989 ± 0.001, 0.714 ± 0.004 (all, p
0.830 ± 0.003, 0.733 ± 0.008 (all, p < 0.0001); (D) 1 ± 0.016, 0.681 ± 0.006, 0.95
(E) 1 ± 0.005, 0.671 ± 0.001, 0.760 ± 0.004, 0.743 ± 0.003, 0.816 ± 0.001, 0.849
triplicate and not by biological triplicate. All statistical analyses in this figurelevels in the #5 and B7Rm iPSC-derived cells (Figure 5M-O).
Treatment of the #5 iPSC-derived rod photoreceptor cells
with each of the reagents described above also resulted in
the reduced expression of the autophagy markers LC3,
ATG5, and ATG7 (Figure 5P-R).
Discussion
We generated an iPSC line from the somatic cells of a pa-
tient with RP who carried the rhodopsin E181K mutation,
and this iPSC line was used to derive rod photoreceptor
cells that harbored the same rhodopsin mutation. These
cells were then used to demonstrate that the E181K muta-
tion was indeed a pathogenic, disease-causing mutation
and were used to explore the underlying molecular mech-
anisms and potential therapeutic approaches.
A considerable number of genetic abnormalities are rec-
ognized as the cause of RP pathogenesis. Although mul-
tiple genes and multiple mutations within these genes have
been linked to RP, some of these mutations may, in fact, be
non-pathogenic, and, in some cases, patients may have
more than one mutation in their genome [1]. Moreover,
RP is exceptionally heterogeneous, and the same mutation
in different individuals may produce different clinical con-
sequences due, in part, to the different genetic back-
grounds of the individuals [1]. Given these complications,
it has been challenging to determine the precise genotype-
phenotype association of a large number of mutations. In
the present study, using human iPSCs and gene manipula-
tion, we demonstrated that the correction of a rhodopsin
gene mutation reversed photoreceptor cell loss in the
iPSC-derived rod photoreceptor cells of an RP patient,
whereas mutagenesis of the rhodopsin gene in control
iPSCs increased cell loss. These experiments directly dem-
onstrated the pathogenicity of the rhodopsin mutation in
an in vitro system. When utilizing iPSCs to analyze disease
pathogenesis, there may be a concern that the observed
phenotype might be related to differences in the cell linesr cells. (A) Relative number of pNrl-EGFP-positive rod photoreceptor
N = 9. (B-E) Relative mRNA levels of BiP (B), CHOP (C), BID (D), and
ICAR, NQDI-1, and salubrinal at 5 weeks after differentiation. Each
ER stress and apoptotic markers were suppressed. N = 3 for B-E.
± SD relative to cont. (with each p-values of marked by *) for Cont.,
6, 3.67 ± 1.22, 2.99 ± 0.513, 2.19 ± 1.12 (all, p < 0.0001); (B) 1 ± 0.005,
< 0.0001); (C) 1 ± 0.002, 0.608 ± 0.003, 0.842 ± 0.009, 0.802 ± 0.003,
4 ± 0.007, 0.864 ± 0.002, 0.934 ± 0.004, 0.816 ± 0.008 (all, p < 0.0001);
± 0.006 (all, p < 0.0001). These data were obtained by technical
were carried out by One-way ANOVA Dunnett’s test.
Figure 5 (See legend on next page.)
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Figure 5 Autophagy markers in iPSC-derived rod photoreceptor cells. Immunostaining of pNrl-EGFP-positive cells (green: A, D, G and J) and
immunocytochemistry using anti-LC3 antibody (magenta: B, E, H and K), and their merged images (C, F, I, L). Arrowheads indicated pNrl-EGFP-
and LC3-double positive cells. Scale bar: 20 μm. The autophagy marker molecules LC3 (M, P), ATG5 (N, Q), and ATG7 (O, R) were analyzed using
real-time PCR in the pNrl-EGFP-positive rod photoreceptor cells derived from each iPSC line in the absence of treatment (M-O) and in #5
iPSC-derived cells following therapeutic treatment (P-R), both at 5 weeks of culture. Autophagy was suppressed in the #5Rw and B7 iPSC-derived
cells and in the #5 iPSC-derived cells with each treatment. N = 3 for all. Rapa., rapamycin; Salub., salubrinal. *p < 0.05, ***p < 0.001. Mean ± SD
(with each p-values of marked by *) for #5, #5Rw, B7, B7#Rm in (M) 1 ± 0.010, 0.830 ± 0.005 (p < 0.0001), 0.881 ± 0.008, 0.943 ± 0.003 (p = 0.002);
(N) 1 ± 0.007, 0.747 ± 0.005 (p < 0.0001), 0.836 ± 0.005, 1.06 ± 0.006 (p < 0.0001); (O) 1 ± 0.004, 0.849 ± 0.003 (p < 0.0001), 0.842 ± 0.003, 1.04 ± 0.003
(p < 0.0001). Mean ± SD relative to cont. (with each p-values of marked by *), for Cont.. Rapa., PP242, AICAR, NQDI-1, Salbr. for (P) 1 ± 0.010,
0.601 ± 0.001, 0.873 ± 0.011, 0.784 ± 0.004, 0.885 ± 0.004, 0.757 ± 0.002 (all, p < 0.0001); (Q) 1 ± 0.007, 0.599 ± 0.001, 0.867 ± 0.004, 0.772 ± 0.003,
0.872 ± 0.0003, 0.683 ± 0.001 (all, p < 0.0001); (R) 1 ± 0.004, 0.675 ± 0.001, 0.924 ± 0.003, 0.818 ± 0.002, 0.879 ± 0.001, 0.818 ± 0.004 (all, p < 0.0001).
These data were obtained by technical triplicate and not by biological triplicate. Statistical analyses in M-O and P-R were carried out by Student’s
T test and by One-way ANOVA Dunnett’s test, respectively.
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[22]. Thus, to exclude such a concern, we investigated
the effect of correcting the genetic defect in the patient-
derived iPSC line, aiming to clarify the genotype-
phenotype causal relationship.
This genetically well-controlled study was facilitated by
the use of HDAdV for the gene targeting of human iPSCs.
HDAdV was originally developed to overcome host im-
mune responses to E1-deleted AdV, the adenovirus com-
monly used for gene transfer [23]. Because the viral genes
are completely removed from the vector genome, the
HDAdV system is less toxic to the infected cells. More-
over, the increased cloning capacity of HDAdV when
combined with negative selection was shown to result in
an increased frequency of targeted integrations in human
iPSCs [24]. In the present study, the use of this method-
ology resulted in the successful generation of targeted
iPSCs, and large gene targeting in iPSCs will be useful for
establishing the pathogenesis of various candidate genes
associated with hereditary diseases [25]. Moreover, be-
cause HDAdV gene transfer does not result in the transfer
of viral sequences, this technique may also have the poten-
tial to be used for gene therapy via iPSC transplantation.
Indeed, the HDAdV gene transfer system has several
advantages compared to other genome-editing methods,
such as CRISPR (clustered regularly interspaced short
palindromic repeats) or TALEN (Transcription Activator-
Like Effector Nucleases), which may induce off-target
alterations [26]. Fu et al. reported that the off-target sites
caused by CRISPR harbored up to five mismatches, and
many sites were mutagenized with frequencies comparable
to those observed at the intended on-target site. This is
because the DNA break caused by Cas9 nuclease, which
leads to the genome editing, can be guided by simple
base-pair complementarity between the first 20 nucleo-
tides of an engineered guide RNA-target DNA interface
and can be easily misguided by sensing mismatched se-
quences. Undesired off-target sites when using TALEN
are also related to unintended DNA cleavage [27]. In con-
trast, the HDAdV gene transfer system does not requireDNA cleavage but instead requires homologous recom-
bination; therefore, this technique results in few off-target
effects.
Clinical trials using several therapeutic approaches for
RP are currently in progress. One example is retinal pig-
ment epithelium-specific 65-kDa protein (RPE65) gene
therapy for the treatment of Leber’s congenital amaurosis
(LCA); this autosomal recessive abnormality is caused by a
loss-of-function of RPE65 and can thus be treated through
the introduction of the normal gene.
In contrast, a different approach is required for auto-
somal dominant diseases caused by mutations that result
in a toxic gain-of-function protein. A randomized trial of
ciliary neurotrophic factor (CNTF) was performed to
evaluate the safety and efficacy of this factor with regard
to the visual functions of RP patients [28]. Although this
treatment caused no serious adverse events, retinal sensi-
tivity was reduced, possibly due to rhodopsin degradation
[29] in response to CNTF. Thus, definitive therapeutic ap-
proaches for RP have not yet been established. Our study
using a patient’s iPSC-derived photoreceptor cells offers a
novel approach for the evaluation of potential of new
therapeutics.
We found that treatment with salubrinal, a selective in-
hibitor of eIF2α, led to an increased number of #5 iPSC-
derived rod photoreceptor cells. Additionally, the treated
cells showed reduced levels of ER stress and apoptotic
markers, suggesting that the rod photoreceptor cell death
caused by the rhodopsin E181K mutation could be sup-
pressed by inhibiting protein synthesis, including the syn-
thesis of the abnormal rhodopsin. Treatment with NQDI-1,
an inhibitor of ASK1 activation, also increased the survival
of the mutant rod photoreceptor cells, consistent with the
idea that apoptosis is regulated by the ER stress-induced
Ire-1α-ASK1-JNK pathway [30,31].
Based on these findings, we further investigated the
ER stress-induced apoptosis pathway using additional re-
agents that modify this signaling pathway. Treatment
with rapamycin reduced ER stress markers in the #5
iPSC-derived rod photoreceptor cells and significantly
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tant rhodopsin protein, which increases ER stress, may
have activated the mTORC1-regulated Ire1α-ASK1-JNK
apoptotic pathway [30]; mTORC1 can further increase cell
death through a positive feedback mechanism, resulting in
increased protein synthesis, including the mutated rhod-
opsin [30]. Thus, the protective effect of rapamycin in
these cells may be due to the suppression of the vicious
cycle between the UPR (unfolded protein response) and
mTORC1 pathways. This FDA-approved drug (rapamy-
cin) can be reassessed to treat RP; however, further studies
are required. In contrast to rapamycin, PP242 inhibits
both mTORC1 and mTORC2; the latter is also influenced
by UPR, and mTORC2 signaling induces survival signal-
ing via AKT activation [30]. This contradictory action of
mTORC2 may limit the overall effect of PP242 on the
suppression of cell death.
AMPK activation through AICAR treatment also exhib-
ited a protective effect by reducing ER stress and increasing
photoreceptor cell survival. Previous studies have shown
that AMPK suppresses mTORC1 indirectly through the
phosphorylation and activation of the tuberous sclerosis
complex (TSC) [30,32]. Additionally, extensive studies have
also revealed that the activity of mTORC1 is modulated by
intracellular energy levels through multiple mechanisms,
and AMPK is reported to directly phosphorylate multiple
components of the mTORC1 pathway [32].
Autophagy is a process that involves the degradation of
proteins and organelles in response to various forms of
cellular stress, including ER stress [14]. The unfolded or
misfolded proteins in the ER lumen that cause ER stress
are translocated to the cytoplasm where they are de-
graded. During this process, the ubiquitin proteasome sys-
tem and autophagy act as degradation systems for the
unfolded proteins. Thus, disturbing autophagy renders the
cells vulnerable to ER stress, as autophagy plays important
roles in cell survival after ER stress [15]. The absence of
autophagy may cause neurodegenerative diseases [33,34],
and autophagy has also been shown to cause apoptosis
in some diseases by destroying cellular components [35].
Accordingly, we examined the expression of autophagy
markers in the iPSC-derived rod photoreceptor cells with
or without the rhodopsin mutation. We found that the
levels of autophagy markers changed in parallel with the
levels of ER stress and the levels of the apoptosis markers.
We interpret this result that the decrease in autophagy
markers following the drug treatments may have resulted
from the decreased demand for autophagy following the
suppression of ER stress.
In the present study, to examine the effects of various
drugs, and characterize the ER stress and autophagy
marker expression, we could obtain consistent results with
low p-values in the triplicated real-time PCR experiment
(Figures 4 and 5). Strictly, however, these results can beinterpreted as follows. Because of the limitation of the cul-
ture scale, we had to put each iPSC-derived pNrL-GFP
positive rod photoreceptor cells which were obtained from
each culture well together, before reverse transcription.
Thus, each real-time PCR data in Figures 4 and 5 was ob-
tained using the same RT-product as a template, rather
than biological triplicate. These experimental conditions
can explain why such low p-values for the mRNA expres-
sion changes by various drugs’ treatment. Thus, in the fu-
ture investigations, these results should be re-confirmed
using biological triplicate by performing larger scale of
iPSC cultures and subsequent photoreceptor differenti-
ation assays.
To obtain target cells that could be used to explore dif-
ferent therapeutic approaches, we used Lamba’s differenti-
ation method [16], which allows the cells to express rod
photoreceptor cell markers within only a few weeks. Con-
sidering that the human photoreceptor require more time
to mature in vivo, it is possible that the photoreceptor cells
derived using this method have artificial intracellular mi-
croenvironments. In fact, there are several protocols for
retinal differentiation that involve months of culture
[11,12,36,37]. However, the method used in the present
study required less time and constitutes an efficient strat-
egy for creating cells that can be used to examine patho-
genic genes and screen novel therapeutics, which can be
then applied in industrial uses.
Conclusions
In summary, the generation of iPSCs from an RP patient
was a valuable approach to demonstrate a causative link
between a pathogenic mutation and a cellular pheno-
type. The use of iPSCs derived from RP and control in-
dividuals, combined with the manipulations of the gene
of interest using HDAdV, allowed us to examine the ef-
fects of normal and mutant rhodopsin in otherwise gen-
etically identical rod photoreceptor cells. Further studies
using similar systems should help to reveal the molecu-
lar mechanisms underlying other genetic diseases and
could serve as a cellular platform for the evaluation of
potential therapeutics, including the large-scale screen-
ing of compound libraries.
Methods
This study followed the tenets of the Declaration of
Helsinki and was approved by the ethics committee at
Keio University School of Medicine (Approval No.
2008016).
Isolation of human skin cells and generation of iPSCs
Skin cells were obtained from a 53-year-old Japanese fe-
male RP patient by a skin-punch biopsy after the patient
gave her written, informed consent. These cells were then
infected with retroviruses encoding four reprogramming
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scribed, to generate a human iPSC line, RP#5 (#5), [15,38].
The control iPSC line [201B7 (B7)], which was generated
using the same method described for #5, was kindly pro-
vided by Dr. Shinya Yamanaka of Kyoto University [15].
The sequences of the rhodopsin genes in the iPSCs (see
Additional file 1: Table S1) and the immunostaining of
pluripotent markers (see Additional file 2: Table S2) were
analyzed; teratoma formation was confirmed as previously
described [38].
Preparation of HDAdVs and gene targeting
HDAdVs were prepared as previously described to gener-
ate gene-targeted iPSCs (#5Rw and B7Rm clones) (see Re-
sults and Additional file 3).
Differentiation, collection, and analyses of rod
photoreceptor cells
The in vitro differentiation of the rod photoreceptor cells
from iPSCs was performed as previously reported (see
Additional file 3) [16]. The differentiated cells were in-
fected with Ad-pNrl-EGFP, which was generated using the
pENTR1A plasmid harboring the Nrl promoter region
(kindly provided by Dr. Anand Swaroop, NIH, MD) [19],
2 days prior to each analysis. The cells were suspended in
PBS containing 10 μg/ml propidium iodide (PI) to stain
the non-viable cells and were sorted to collect the
EGFP-positive viable cells using a triple-laser MoFlo
(Dako), FACS Calibur or FACS Aria (BD Biosciences)
flow cytometer. The collected cells were counted or
used for a real-time PCR analysis (see Additional file 1:
Table S1). For real-time PCR analyses, the differentiated
cells were summed up from each culture well according
to the iPSC groups or the treatment groups. Annexin V
staining was performed using Annesin V-Biotin Apop-
tosis Detection Kit (Bio Vision), followed by the staining
with Streptoavidin, Allophcocyanin, crosslinked, conju-
gated antibody (Life Technoloties). Immunohistochemi-
cal analyses were performed using antibodies listed in
Additional file 2: Table S2. Images were obtained using
LSM-710 confocal (Zeiss) microscopes.
Treatment protocol
The iPSC-derived cells were treated with the following
drugs after 3 weeks of differentiation: 10 nM rapamycin
(Selleckchem.com), 500 nM PP242 (Sigma-Aldrich), 2 μM
5-aminoimidazole-4-carboxyamide ribonucleoside (AICAR,
Santa Cruz), 500 nM Nuclear Quality Assurance-1 (NQDI-
1, Axon Medchem), and 3 μM salubrinal (Millipore).
Statistical analyses
All the results are expressed as the mean ± SD. The differ-
ences were analyzed using the Student’s T test (between 2
groups) and Dunnett’s test (among 6 groups), and thedifferences were considered significant when p < 0.05. All
statistical tests were performed using IBM SPSS statistics
Ver.19 (IBM, Armonk, NY) and confirmed using Stata13
(Light Stone, Tokyo, Japan).
Additional files
Additional file 1: Table S1. Primer list.
Additional file 2: Table S2. Antibody list.
Additional file 3: Supplementary materials and methods.
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